Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
This article was originally published in PharmAsia News
Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations
You may also be interested in...
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.
Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call
Company has sent a "Dear Dr." letter describing rare cases of liver problems and will also send additional data to FDA from the clinical trials.